IAG’ Research Team at Presenting ESMO, European Society for Medical Oncology Meeting
Dr. Roettger will discuss the challenges biotech companies face in oncology trials and explore IAG’s novel strategies to include advanced imaging biomarkers in the clinical development process. Given the increasing need for collaboration in therapy development, Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships and targeted development strategies.
IAG partners with biotechnology and pharmaceutical companies and supports their clinical research programmes with its scientific, operational and technological expertise. IAG takes a holistic approach to biotech’s clinical development and brings together:
- An efficient purpose-built cloud based system with embedded quality controls for trial data management (DYNAMIKA)
- Patented methodologies for quantitative assessment of treatment efficacy and safety
- Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
- Ensures that its bio-pharmaceutical clients gain the most benefits of early objective decision making on their treatment efficacy from utilizing advanced imaging techniques in their trials
Discover our risk assessment and management strategies to overcome the challenges in your oncology trial by contacting IAG at email@example.com
The ESMO Congress is the most influential annual meeting for oncology professionals in Europe. The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), will bring cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back. This exciting partnership creates a unique cancer congress in Europe with huge scientific reach and the true potential to improve the lives of cancer patients. More information on the conference here.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com